en Gastroentrology Gastroentrology Original Article Original Article <p><span style="font-size:14px"><span style="font-family:Times New Roman"><strong><em><span style="color:blue">Background</span></em></strong><em><span style="color:blue">:</span></em> The aim of this study was to evaluate the diagnostic accuracy of various non-invasive methods for Non-alcoholic fatty liver disease (NAFLD)<s> </s>diagnosis in an Iranian population. The methods studied included aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) index, aspartate aminotransferase to alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet count index (AP index), fibrosis index (FI), NAFLD fibrosis score (NFS), Forns index, BARD score, BAAT score and PLALA score. The aim of the current study was to correlate these methods with liver stiffness measurement (LSM) and serum fibrosis markers, using FibroScan as the gold standard.<br> <strong><em><span style="color:blue">Methods:</span></em></strong> In a cross-sectional study of 504 patients with NAFLD or non-alcoholic steatohepatitis (NASH), FibroScan examinations were performed and demographic, clinical and biochemical data were collected. Statistical analyses evaluated the performance of each diagnostic panel, calculating sensitivity, specificity, positive predictive value, negative predictive value and accuracy.<br> <strong><em><span style="color:blue">Results:</span></em></strong> The APRI had high specificity (97.27%) but low sensitivity (4.12%) and limited discriminatory power AUC: 0.50) in the fibrosis panel. In contrast, Forns index and NFS had better AUC values (0.64 and 0.63, respectively), with the NFS having a sensitivity of 80%, indicating potential for broad-based screening. In the cirrhosis panel, the APRI was characterized by high specificity (98.21%) but had low sensitivity (4%) and limited discriminatory power (AUC: 0.51), while the FIB-4 had the highest AUC (0.67) and a sensitivity of 60%, suggesting its efficacy as a screening tool.<br> <strong><em><span style="color:blue">Conclusion</span></em></strong><em><span style="color:blue">:</span></em> NFS and FIB-4 showed promising performance among the evaluated panels for population screening.</span></span><br> &nbsp;</p> NAFLD, FibroScan, Fibrosis, FIB-4, APRI, Non-invasive, AST/ALT. 275 283 http://caspjim.com/browse.php?a_code=A-10-2343-2&slc_lang=en&sid=1 Mahsa Mohammadi Dr.mahsa.mohammadi1989@gmail.com 100319475328460052243 100319475328460052243 No Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran Keyvan Aminian keyvanaminian@yahoo.com 100319475328460052244 100319475328460052244 No Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran Farahnaz Joukar farajov@gmail.com 100319475328460052245 100319475328460052245 No Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran Mohsen Rajabnia dr.rajabnia@outlook.com 100319475328460052246 100319475328460052246 No Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran Khaled Rahmani Khaledrahmani111@yahoo.com 100319475328460052247 100319475328460052247 No Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran Alireza Doostian alireza.doostian1374@yahoo.com 100319475328460052248 0009-0006-0296-7073 No Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Fariborz Mansour-Ghanaei fmansourghanaei@gmail.com 100319475328460052249 100319475328460052249 Yes Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran